Physician oversight independent of the business model
A membership or subscription business model does not change the need for physician-level purchasing accountability. Keep the medical director's documentation review separate from membership sales and marketing decisions made elsewhere in the business.
Confirm the account holder's NPI verification stays current, and document the physician's role distinctly from general clinic management.
- Keep physician-level purchasing accountability regardless of business model
- Separate the medical director's documentation review from sales and marketing
- Confirm the account holder's NPI verification stays current
- Document the physician's role distinctly from general clinic management
Tracking documentation across a broader product panel
If your clinic carries more than one biologics product family, track each family's documentation separately rather than as one undifferentiated list, since lot-level detail still applies to each product.
A Wharton's jelly product and an exosome product carry different sourcing and regulatory considerations. FDA states there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions for any product belong to the physician and their own regulatory counsel.
- Track documentation separately by product family
- Scale inventory systems to a broader panel without losing lot-level detail
- Review each product family's regulatory considerations independently
- Reassess panel breadth periodically against actual demand
Separating sourcing documentation from consumer marketing
FDA has issued warning letters to distributors and clinics over disease and treatment claims in consumer-facing marketing. Keep sourcing documentation, certificates of analysis, donor eligibility summaries, and lot release records, separate from membership marketing, website copy, and social content.
FDA reads marketing and social content as evidence of intended use. Review those materials, as well as sourcing and release documentation, with counsel on a regular basis.
These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.
- Keep sourcing documentation separate from all public-facing marketing
- Have counsel review website and social content for claims language
- Remember that marketing content can be read as evidence of intended use
- Audit existing marketing materials periodically for claims drift
Reviewing consumer-facing messaging at the same standard as advertising
Consumer-facing language is held to the same FTC competent-and-reliable-evidence standard that applies to any health product claim, whether it appears in a formal advertisement or an informal channel such as email or social media.
Review member-facing emails, intake materials, and social posts for claims language with the same rigor as a formal advertisement, rather than treating informal channels as lower risk.
- Apply the same claims review to informal channels as to formal advertising
- Review member emails, intake forms, and social posts for claims language
- Confirm marketing claims meet the FTC's competent-and-reliable-evidence standard
- Treat this category as one under active regulatory attention
Frequently asked questions
Who holds purchasing authority in a membership-model wellness clinic?+
Keep physician-level purchasing accountability regardless of the business model, and document that review separately from the membership sales and marketing side of the business.
How should a clinic manage documentation across a broad product panel?+
Track each product family's lot documentation separately, since different product families, such as Wharton's jelly products and exosome products, carry different sourcing and regulatory considerations.
Why does marketing language matter for this category?+
FDA reads a clinic's own marketing and social content as evidence of intended use. Review both formal and informal consumer-facing language with counsel, alongside sourcing and release documentation.